Gabapentin controlled release - Depomed

Drug Profile

Gabapentin controlled release - Depomed

Alternative Names: DM-1796; DM-5689; Gabapentin ER; Gabapentin extended release; Gabapentin Gastric Retention; Gabapentin GR; Gralise; Serada

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Depomed; Elan Corporation
  • Developer Depomed
  • Class Amines; Aminobutyric acids; Analgesics; Antiepileptic drugs; Antimanics; Antiparkinsonians; Anxiolytics; Cyclohexanecarboxylic acids; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; GABA receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Postherpetic neuralgia
  • Discontinued Diabetic neuropathies; Hot flashes

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 04 Mar 2013 Advisory Committee for Reproductive Health Drugs votes against the approval of gabapentin controlled release for Hot flashes in USA
  • 15 Oct 2012 The US FDA sets PDUFA date in May 2013 for NDA review for Hot flashes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top